Clinical Trials Logo

Clinical Trial Summary

Finding a predictive biomarker for IAI could improve the clinical outcome for the mother and the neonate. The aim of this study is to quantify the copy number of circulating cell-free mitochondrial DNA in maternal serum and the placenta compared to controls.the investigators hypothesise that circulating cell-free mitochondrial DNA levels could help predict the likelihood of early inflammation in IAI. In addition, mitochondrial DNA could be a promotor triggering the pathogenesis of systemic inflammation.


Clinical Trial Description

Background: Intra-amniotic infection (IAI) or chorioamnionitis is a common condition seen in obstetrics leading to labor abnormalities such as uterine atony, postpartum bleeding and preterm labor (Schrag et al., 2006). Further adverse effects such as perinatal death, asphyxia, sepsis, pneumonia, respiratory distress and especially neurodevelopmental delay and cerebral palsy are associated with IAI (Buhimschi et al., 2009; Holzman, Lin, Senagore, & Chung, 2007). Diagnosing IAI can be challenging due to its very heterogeneous clinical signs, which are often very insensitive for this condition. Clinical findings such as fever, tachycardia and maternal leukocytosis leave room for multiple differential diagnoses. During apoptosis (due to hypoxia, cell damage or infection) the cell membrane integrity is disturbed, releasing the cytoplasm into the blood circulation. Circulating cell-free mitochondrial DNA acts as a damage associated molecular pattern (DAMP) by activating the innate immune system leading to inflammation (Matzinger, 1994). These DAMPs are evolutionary conserved and have structural similarity to their bacterial ancestor (Zhang et al., 2010). Therefore, cell-free mitochondria can act as a potent agent triggering the immune system in an autoimmune manner as well as a biomarker for cell damage due to infection.

Objective: Finding a predictive biomarker for IAI could improve the clinical outcome for the mother and the neonate. The aim of this study is to quantify the copy number of circulating cell-free mitochondrial DNA in maternal serum and the placenta compared to controls. Investigators hypothesize that circulating cell-free mitochondrial DNA levels could help predict the likelihood of early inflammation in IAI. In addition, mitochondrial DNA could be a promotor triggering the pathogenesis of systemic inflammation.

Methods: For this study the investiagtors planned 2 groups each consisting of 30 patients. The control group are pregnant women without IAI. The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI (meeting the diagnostic criteria for IAI suggested by the National Institute of Child Health and Human Development Workshop). 12ml of venous blood will be drawn from a peripheral venous line in addition to routine blood tests, when the patient arrives at the ward (2 weeks before delivery). A further 12ml of venous blood will be taken from the peripheral venous line, during delivery (during delivery). In addition, 12ml of venous blood will be drawn from the placenta postpartum. In total, 36 ml of blood will be withdrawn in each patient. Circulating cell-free mitochondrial DNA will be quantified in maternal and placental serum by real time quantitative PCR and statistical analysis will be performed by non-parametric tests.

Design: Single center, prospective, observational pilot trial. ;


Study Design


Related Conditions & MeSH terms

  • Fetal Membranes, Premature Rupture
  • Preterm Premature Rupture of Membrane
  • Rupture

NCT number NCT03306719
Study type Observational
Source Medical University of Vienna
Contact Herbert Kiss, MD, PhD
Phone +43140400
Email herbert.kiss@meduniwien.ac.at
Status Recruiting
Phase N/A
Start date April 5, 2017
Completion date December 31, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04963465 - The Accuracy of Amniotic Fluid Ferning in the Second Trimester in the Diagnosis of Preterm Prelabor Rupture of Membranes
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT04294069 - Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial Phase 4
Recruiting NCT03976063 - Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation Phase 3
Completed NCT01503606 - Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane Phase 3
Recruiting NCT04590677 - Prediction of the Onset of Term and Preterm Labour
Recruiting NCT04110704 - Cerclage After Full Dilatation Caesarean Section N/A
Completed NCT03473210 - The Value of Amniopatch in Preterm Premature Rupture of Membranes N/A
Not yet recruiting NCT05328817 - Azithromycin Versus Erythromycin For Preterm Prelabor Rupture of Membranes N/A
Recruiting NCT05353153 - The Psychological Experience of Pathological Pregnancy. Study of the Case of Premature Rupture of Membranes and Evaluation of the Impact of Hypnosis Support N/A
Completed NCT03814278 - Bed Rest After Preterm Premature Rupture of the Membranes N/A
Completed NCT04807543 - Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes Phase 2
Recruiting NCT06443788 - Trans-perineal Ultrasound in Assessment of PPROMs N/A
Not yet recruiting NCT05207800 - Predictive Value of Maternal Serum Pentraxin 3 (PTX 3) and Heparin-binding Protein (HBP) for Chorioamnionitis in Preterm Premature Rupture of Membranes
Recruiting NCT04705935 - Amniochorionic Membrane Cells in the Maternal Blood as a Biomarker for Preterm Birth
Not yet recruiting NCT06396078 - Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) Phase 4
Active, not recruiting NCT06074601 - MIRACLE of LIFE Study
Recruiting NCT04516226 - Vaginal Cleansing With Chlorhexidine Gluconate in Women With Preterm Pre-labor Rupture of Membranes N/A
Not yet recruiting NCT06377397 - Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates Phase 3
Completed NCT04413019 - Domiciliary Versus Hospital Management of PPROM